Clinical trial NCT01088620: Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
Official title: CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: NSCLC
Stage IIIb or IV
Nonsquamous
KRAS-Wildtype
Lead sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Sponsor class: OTHER
Collaborators: name: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
First posted: 2010-03-17
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the progression free survival rate at 6 months is improved by the targeted regimen.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed diagnosis of inoperable stage IIIB or IV primary pulmonary nonsquamous NSCLC (according to UICC staging valid until 2008)
* Sufficient representative sample material for KRAS analysis
* Wild-type KRAS
* Informed consent of the patient
* Aged at least 18 years
* WHO Performance Status 0-2
* At least one unidimensional, measurable tumour parameter according to RECIST
* Life expectancy of al least 12 weeks
* Adequate haematological, hepatic, renal and metabolic function parameters:

  * Leukocytes \> 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Creatinine clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of normal
  * Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of normal
  * Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal

Exclusion Criteria:

* Prior chemotherapy
* Clinically manifest, uncontrolled brain metastases
* Prior radiotherapy of the parameters to be measured
* Peripheral neuropathy NCI grade \> 1
* Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
* Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).
* Serious concurrent diseases.
* Major surgery within the last 4 weeks before recruitment
* On-treatment participation in a clinical study in the period 30 days prior to inclusion.
* Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment.
* Ongoing or active infection, including active tuberculosis or known infection with human immunodeficiency virus.
* Superior vena cava syndrome contraindicating hydration.
* History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
* Patient with mild to moderate renal insufficiency who are unable to interrupt salicylates (like aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDS) for a 5-day period starting 2 days before administration of pemetrexed (8-day period for long-acting agents such as piroxicam). Exception: Low dose aspirin (acetyl salicylic acid) intake up to 150 mg per day is permitted without interruption.
* Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures
* Inability or unwillingness to take folic acid, vitamin B12 supplementation or dexamethasone (or equivalent corticosteroid); or any other inability to comply with protocol or study related procedures
* Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is continuously disease-free
* Known allergic reactions on study medication

Primary outcomes:
measure: Progression free survival rate at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: Determination of the tumour response
timeFrame: 6 months
measure: Duration of response
timeFrame: 6 months
measure: Overall survival
timeFrame: 6 month
measure: Adverse effects / toxicity
timeFrame: 6 months
measure: Quality of life assessment
timeFrame: 6 months
Other outcomes:
Locations:
city: Amberg
country: Germany
facility: Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gesundheitszentrum St. Marien GmbH
city: Berlin
country: Germany
facility: Universitätsklinikum Charité - Campus Mitte
city: Berlin
country: Germany
facility: Charité Campus Benjamin Franklin Medizinische Klinik m. S. Hämatologie und Onkologie
city: Berlin
country: Germany
facility: HELIOS Klinikum Emil von Behring - Lungenklinik Heckeshorn
city: Bochum
country: Germany
facility: Augusta-Kranken-Anstalt gGmbH
city: Bonn
country: Germany
facility: Johanniter-Krankenhaus Bonn
city: Cottbus
country: Germany
facility: Carl-Thiem-Klinikum Cottbus gGmbH
city: Dresden
country: Germany
facility: Medizinische Fakultät Carl Gustav Carus der Technischen Universität Dresden Medizinische Klinik 1
city: Duisburg
country: Germany
facility: Katholisches Klinikum Duisburg/St. Johannes-Hospital
city: Frankfurt (Oder)
country: Germany
facility: Klinikum Frankfurt (Oder) GmbH
city: Großhansdorf
country: Germany
facility: Krankenhaus Großhansdorf GmbH Onkologischer Schwerpunkt
city: Halle/Saale
country: Germany
facility: Krankenhaus - Martha-Maria Halle-Dölau GmbH
city: Halle/Saale
country: Germany
facility: Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Innere Medizin I
city: Jena
country: Germany
facility: Universitätsklinikum Jena, Klinik für Innere Medizin I
city: Kronach
country: Germany
facility: Onkologische Schwerpunktpraxis Dr. Stauch
city: Köln
country: Germany
facility: Kliniken der Stadt Köln, Krankenhaus Merheim
city: Lübeck
country: Germany
facility: UK-SH, Campus Lübeck, Med. Klinik III
city: München
country: Germany
facility: LMU-Klinikum der Universität München, Medizinische Klinik München-Innenstadt
city: Recklinghausen
country: Germany
facility: Oncologianova GmbH
city: Ulm
country: Germany
facility: Uniklinikum Ulm, Klinik für Innere Medizin II, Pneumologie
Study officials:
affiliation: Krankenhaus Martha-Maria Halle-Dölau
name: Wolfgang Schütte, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schuette W, Behringer D, Stoehlmacher J, Kollmeier J, Schmager S, Fischer von Weikersthal L, Schumann C, Buchmann J. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status. Clin Lung Cancer. 2015 Nov;16(6):447-56. doi: 10.1016/j.cllc.2015.05.009. Epub 2015 Jun 2.